The dopamine transporter gene SLC6A3: multidisease risks

Mol Psychiatry. 2022 Feb;27(2):1031-1046. doi: 10.1038/s41380-021-01341-5. Epub 2021 Oct 14.

Abstract

The human dopamine transporter gene SLC6A3 has been consistently implicated in several neuropsychiatric diseases but the disease mechanism remains elusive. In this risk synthesis, we have concluded that SLC6A3 represents an increasingly recognized risk with a growing number of familial mutants associated with neuropsychiatric and neurological disorders. At least five loci were related to common and severe diseases including alcohol use disorder (high activity variant), attention-deficit/hyperactivity disorder (low activity variant), autism (familial proteins with mutated networking) and movement disorders (both regulatory variants and familial mutations). Association signals depended on genetic markers used as well as ethnicity examined. Strong haplotype selection and gene-wide epistases support multimarker assessment of functional variations and phenotype associations. Inclusion of its promoter region's functional markers such as DNPi (rs67175440) and 5'VNTR (rs70957367) may help delineate condensate-based risk action, testing a locus-pathway-phenotype hypothesis for one gene-multidisease etiology.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Attention Deficit Disorder with Hyperactivity* / genetics
  • Dopamine Plasma Membrane Transport Proteins* / genetics
  • Dopamine Plasma Membrane Transport Proteins* / metabolism
  • Haplotypes
  • Humans
  • Mutation
  • Phenotype

Substances

  • Dopamine Plasma Membrane Transport Proteins
  • SLC6A3 protein, human